• SPX
  • $5,969.34
  • 0.35 %
  • $20.63
  • DJI
  • $44,296.51
  • 0.97 %
  • $426.16
  • N225
  • $38,283.85
  • 0.68 %
  • $257.68
  • FTSE
  • $8,262.08
  • 1.38 %
  • $112.81
  • IXIC
  • $19,003.65
  • 0.16 %
  • $31.23
Roivant Sciences Ltd. (ROIV) Stock Price, News & Analysis

Roivant Sciences Ltd. (ROIV) Stock Price, News & Analysis

Currency in USD Disclaimer

$12.53

$0.71

(6.01%)

Day's range
$11.78
Day's range
$12.57
50-day range
$11.05
Day's range
$12.57
  • Country: GB
  • ISIN: BMG762791017
52 wk range
$8.61
Day's range
$13.06


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 11.70
  • Piotroski Score 5.00
  • Grade Buy
  • Symbol (ROIV)
  • Company Roivant Sciences Ltd.
  • Price $12.53
  • Changes Percentage (6.01%)
  • Change $0.71
  • Day Low $11.78
  • Day High $12.57
  • Year High $13.06

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 02/11/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $17.00
  • High Stock Price Target $20.00
  • Low Stock Price Target $12.50
  • Potential Upside/Downside N/A
  • Consensus Rating Strong Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) $5.23
  • Trailing P/E Ratio 2
  • Forward P/E Ratio 2
  • P/E Growth 2
  • Net Income $4.35 B

Income Statement

Quarterly

Annual

Latest News of ROIV

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Roivant Sciences Ltd. Frequently Asked Questions

  • What is the Roivant Sciences Ltd. stock price today?

    Today's price of Roivant Sciences Ltd. is $12.53 — it has increased by +6.01% in the past 24 hours. Watch Roivant Sciences Ltd. stock price performance more closely on the chart.

  • Does Roivant Sciences Ltd. release reports?

    Yes, you can track Roivant Sciences Ltd.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Roivant Sciences Ltd. stock forecast?

    Watch the Roivant Sciences Ltd. chart and read a more detailed Roivant Sciences Ltd. stock forecast to see what analysts suggest you do with its shares.

  • What is Roivant Sciences Ltd. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Roivant Sciences Ltd. stock ticker.

  • How to buy Roivant Sciences Ltd. stocks?

    Like other stocks, ROIV shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Roivant Sciences Ltd.'s EBITDA?

    Roivant Sciences Ltd. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Roivant Sciences Ltd.’s financial statements.

  • What is the Roivant Sciences Ltd.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is 34.8485596378, which equates to approximately 3,484.86%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Roivant Sciences Ltd. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Roivant Sciences Ltd.'s financials relevant news, and technical analysis. Roivant Sciences Ltd.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Roivant Sciences Ltd. stock currently indicates a “sell” signal. For more insights, review Roivant Sciences Ltd.’s technical analysis.

  • A revenue figure for Roivant Sciences Ltd. for its last quarter?

    Roivant Sciences Ltd. published it's last quarterly revenues at $4.48 M.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.